Paul Giannasca
Keine laufenden Positionen mehr
Karriereverlauf von Paul Giannasca
Ehemalige bekannte Positionen von Paul Giannasca
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
OraVax, Inc.
 OraVax, Inc. BiotechnologyHealth Technology Part of Sanofi, OraVax, Inc. is a company that has a slick name that taps into the words 'oral' and 'vaccine' in a subtle way. The company is based in Cambridge, MA. The company is a possible oral health brand, medical licensing service, app, or chemicals company. OraVax was acquired by Acambis Plc, part of Sanofi from September 22, 2008 on May 11, 1999 for $17.79 million. | Corporate Officer/Principal | - | - |
| GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | 31.03.2011 | - |
Acambis Plc
 Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Corporate Officer/Principal | - | - |
Ausbildung von Paul Giannasca
| Fairleigh Dickinson University | Undergraduate Degree |
| University of Massachusetts | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| Vereinigtes Königreich | 2 |
Operativ
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Health Technology |
OraVax, Inc.
OraVax, Inc. BiotechnologyHealth Technology Part of Sanofi, OraVax, Inc. is a company that has a slick name that taps into the words 'oral' and 'vaccine' in a subtle way. The company is based in Cambridge, MA. The company is a possible oral health brand, medical licensing service, app, or chemicals company. OraVax was acquired by Acambis Plc, part of Sanofi from September 22, 2008 on May 11, 1999 for $17.79 million. | Health Technology |
- Börse
- Insiders
- Paul Giannasca
- Erfahrung
